These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 11937604)

  • 1. External and internal dose to individuals after (131)I outpatient therapy.
    Wooten WW
    J Nucl Med; 2002 Apr; 43(4):575; author reply 575. PubMed ID: 11937604
    [No Abstract]   [Full Text] [Related]  

  • 2. 131I therapy: inpatient or outpatient?
    de Klerk JM
    J Nucl Med; 2000 Nov; 41(11):1876-8. PubMed ID: 11079498
    [No Abstract]   [Full Text] [Related]  

  • 3. Definitive improvement in the approach to the treated patient as a radioactive source.
    Lubin E
    J Nucl Med; 2002 Mar; 43(3):364-5. PubMed ID: 11884496
    [No Abstract]   [Full Text] [Related]  

  • 4. Irradiating the thyroid. How to protect yourself and others.
    Jankowski CB
    Am J Nurs; 1996 Oct; 96(10):50-4. PubMed ID: 8863650
    [No Abstract]   [Full Text] [Related]  

  • 5. Radiation exposure for 'caregivers' during high-dose outpatient radioiodine therapy.
    Marriott CJ; Webber CE; Gulenchyn KY
    Radiat Prot Dosimetry; 2007; 123(1):62-7. PubMed ID: 16825250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiation safety precautions with 131iodine therapy.
    Greenfield LD; Herman MW; Patrick J
    Cancer Nurs; 1978 Oct; 1(5):379-84. PubMed ID: 250446
    [No Abstract]   [Full Text] [Related]  

  • 7. 'Knowingly and willingly in the support and comfort of a patient'.
    Harding LK; Thomson WH
    Nucl Med Commun; 1995 Nov; 16(11):877-8. PubMed ID: 8587751
    [No Abstract]   [Full Text] [Related]  

  • 8. Radiation protection issues associated with nuclear medicine out-patients.
    Thomson WH; Harding LK
    Nucl Med Commun; 1995 Nov; 16(11):879-92. PubMed ID: 8587752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Physical and technical quality assurance and radiation protection in transperineal interstitial permanent prostate brachytherapy with 125-iodine seeds].
    Kaulich TW; Lamprecht U; Paulsen F; Lorenz J; Maurer U; Loeser W; Bichler KH; Nüsslin F; Bamberg M
    Strahlenther Onkol; 2002 Dec; 178(12):667-75. PubMed ID: 12491054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Could the treatment of differentiated thyroid carcinoma with 3.7 and 5.55 GBq of (131I)NaI, on an outpatient basis, be safe?
    de Carvalho JW; Sapienza M; Ono C; Watanabe T; Guimarães MI; Gutterres R; Marechal MH; Buchpiguel C
    Nucl Med Commun; 2009 Jul; 30(7):533-41. PubMed ID: 19436231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NRC absorbed dose reconstruction for family member of 131I therapy patient: case study and commentary.
    Marcus CS; Siegel JA
    J Nucl Med; 2004 Apr; 45(4):13N-6N, 37N. PubMed ID: 15073236
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of thyroid carcinoma: emphasis on high-dose 131I outpatient therapy.
    Parthasarathy KL; Crawford ES
    J Nucl Med Technol; 2002 Dec; 30(4):165-71; quiz 172-3. PubMed ID: 12446749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tracking the origin of the NRC 30-mCi rule.
    Siegel JA
    J Nucl Med; 2000 Oct; 41(10):10N-12N, 15N-16N. PubMed ID: 11037984
    [No Abstract]   [Full Text] [Related]  

  • 14. Outpatient therapeutic 131I for thyroid cancer.
    Panzegrau B; Gordon L; Goudy GH
    J Nucl Med Technol; 2005 Mar; 33(1):28-30. PubMed ID: 15731017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perspectives of U.S. government agencies on the potential role of greater scientific understanding of low-dose radiation effects in establishing regulatory health protection guidance.
    Tenforde TS; Brooks AL
    Health Phys; 2009 Nov; 97(5):516-8. PubMed ID: 19820462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New NRC patient release guidelines: major quality of life & cost-containment benefits.
    Grigsby PW; Baker SM; Siegel BA; Eichling JO
    Adm Radiol J; 1998 Apr; 17(4):18-21. PubMed ID: 10181525
    [No Abstract]   [Full Text] [Related]  

  • 17. [Environmental radiation dose monitor after 125I radioactive seed implantation].
    Zhuo SQ; Chen L; Zhang FJ; Zhao M; Zhang L; Liu J; Li K; Wu PH; Zheng QS; Wang Y
    Ai Zheng; 2007 Jun; 26(6):666-8. PubMed ID: 17562278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between external exposure and activity in patients undergoing 131I thyroid cancer therapy.
    Barquero R; Basurto F; Vega-Carrillo HR; Iñiguez MP; Ferrer N; Esteban R
    Health Phys; 2008 Aug; 95(2):227-33. PubMed ID: 18617804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Problems with radiation protection for adjuvant radiotherapy of thyroid cancer].
    Siekierzyński M
    Wiad Lek; 2001; 54 Suppl 1():307-11. PubMed ID: 12182040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiation protection issues.
    O'Doherty MJ; Barrington SF; Kettle AG; Mountford PJ; Coakley AJ
    Nucl Med Commun; 1996 May; 17(5):443-6. PubMed ID: 8736524
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.